(Q44513458)

English

Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

3 December 2017

Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial (English)

1 reference

Europe PubMed Central

3 December 2017

phase III clinical trial

0 references

1 reference

ChEBI release 2020-05-28

1 reference

based on heuristic

inferred from title

Bonaventura Clotet Sala

3

object named as

Bonaventura Clotet

1 reference

Europe PubMed Central

3 December 2017

Kiat Ruxrungtham

6

object named as

Kiat Ruxrungtham

1 reference

Europe PubMed Central

3 December 2017

author name string

Calvin J Cohen

1

1 reference

Europe PubMed Central

3 December 2017

Jaime Andrade-Villanueva

2

1 reference

Europe PubMed Central

3 December 2017

Jan Fourie

4

1 reference

Europe PubMed Central

3 December 2017

Margaret A Johnson

5

1 reference

Europe PubMed Central

3 December 2017

Hao Wu

7

1 reference

Europe PubMed Central

3 December 2017

Carmen Zorrilla

8

1 reference

Europe PubMed Central

3 December 2017

Herta Crauwels

9

1 reference

Europe PubMed Central

3 December 2017

Laurence T Rimsky

10

1 reference

Europe PubMed Central

3 December 2017

Simon Vanveggel

11

1 reference

Europe PubMed Central

3 December 2017

Katia Boven

12

1 reference

Europe PubMed Central

3 December 2017

THRIVE study group

13

1 reference

Europe PubMed Central

3 December 2017

language of work or name

0 references

publication date

1 July 2011

1 reference

Europe PubMed Central

3 December 2017

1 reference

Europe PubMed Central

3 December 2017

378

1 reference

Europe PubMed Central

3 December 2017

9787

1 reference

Europe PubMed Central

3 December 2017

229-237

1 reference

Europe PubMed Central

3 December 2017

Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960983-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety and tolerance of efavirenz in different antiretroviral regimens: results from a national multicenter prospective study in 1,033 HIV-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960983-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Short-term antiviral activity of TMC278--a novel NNRTI--in treatment-naive HIV-1-infected subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960983-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960983-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960983-5

7 January 2021

based on heuristic

inferred from DOI database lookup

A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960983-5

7 January 2021

based on heuristic

inferred from DOI database lookup

A comparison between cystatin C, plasma creatinine and the Cockcroft and Gault formula for the estimation of glomerular filtration rate

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960983-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Efavirenz versus nevirapine in current clinical practice: a prospective, open-label observational study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960983-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960983-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical, virologic, and immunologic response to efavirenz-or protease inhibitor-based highly active antiretroviral therapy in a cohort of antiretroviral-naive patients with advanced HIV infection (EfaVIP 2 study).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960983-5

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960983-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960983-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960983-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Efavirenz or nevirapine in three-drug combination therapy with two nucleoside-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960983-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Once-daily versus twice-daily lamivudine, in combination with zidovudine and efavirenz, for the treatment of antiretroviral-naive adults with HIV infection: a randomized equivalence trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960983-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960983-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Abacavir once or twice daily combined with once-daily lamivudine and efavirenz for the treatment of antiretroviral-naive HIV-infected adults: results of the Ziagen Once Daily in Antiretroviral Combination Study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960983-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960983-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Recruitment of HIV/AIDS treatment-naïve patients to clinical trials in the highly active antiretroviral therapy era: influence of gender, sexual orientation and race

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960983-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of TMC278 in treatment-naïve, HIV-1-infected patients with HBV/HCV co-infection enrolled in the phase III ECHO and THRIVE trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960983-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(11)60983-5

1 reference

Europe PubMed Central

3 December 2017

1 reference

Europe PubMed Central

3 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44513458&oldid=2026571311"